齐拉西酮联合疏肝解郁胶囊治疗精神分裂症临床疗效观察

Clinical efficacy observation of Ziprasidone combined with Shuganjieyu capsules intreatment of schizophrenia

目的:观察齐拉西酮联合疏肝解郁胶囊治疗精神分裂症的临床疗效。方法:选取60例住院抑郁型精神分裂症患者,按抛硬币分组法分为观察组(32例)和对照组(28例);两组均给予齐拉西酮抗精神病药物系统治疗,观察组在此基础上增加疏肝解郁胶囊,治疗时间均为6周。治疗前后,采用阳性和阴性症状量表(PANSS)和卡尔加里精神分裂症抑郁量表中文版(CDSS-C)评定两组的临床疗效。结果:治疗前,两组PANSS和CDSS-C总分评分均无统计学差异(P>0.05);治疗后,两组患者间PANSS总分和阴性症状分及CDSS-C评分比较差异均有显著统计学意义(P<0.01)。结论:齐拉西酮联合疏肝解郁胶囊治疗精神分裂症可明显提高临床治疗效果,降低抑郁,有助于患者的临床康复。

Objective To observe clinical efficacy of Ziprasidone combined with Shuganjieyu capsules in treatment of schizo-phrenia. Methods： 60 inpatients ＂with depressive schizophrenia ＂were divided into observation group（32 patients） and control group（28 patients） according to the coin tossing method. The two groups were all systematically treated by Ziprasidone. Besides, the observation group was added with Shuganjieyu capsules. The treatment time was two weeks. Before and after the treatment, the clinical treatment effects of the two groups were evaluated with positive and negative symptom scale （PANSS） and Calgar^^ depression scale for schizo-phrenia （CDSS-C）. Results： Before the treatment, the differences of thetotal scores of PANSS and CDSS-C of the two groups were not statistically significant （ P〉0. 05） ; however, after the treatment, the differences were statistically significant （P〈0.05） . Conclu-sions ：Ziprasidone combined with Shuganjieyu capsules in the treatment ofschizophrenia can obviously improve the clinical treatment effects, reduce depression, and is conducive to rehabilitation of the patients.